ArriVent BioPharma, Inc. (AVBP) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AVBP currently has 45.1M outstanding shares. with moderate dilution risk from 9.58M authorized shares representing 21.3% potential dilution. The company has significantly diluted shareholders by 38.72% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 11, 2026 |
10-Q filing | 45.1M shares outstanding |
45M | 9.6M |
| Aug 11, 2025 |
10-Q filing | 40.6M shares outstanding |
41M | 9.6M |
| May 12, 2025 |
10-Q filing | 33.9M shares outstanding |
34M | 9.6M |
| Mar 03, 2025 |
10-K filing | 31.5M shares outstanding |
31M | 9.6M |
| Nov 14, 2024 |
10-Q filing | 33.6M shares outstanding |
34M | 9.6M |
| Aug 14, 2024 |
10-Q filing | 33.5M shares outstanding |
34M | 9.6M |
| May 08, 2024 |
10-Q filing | 33.5M shares outstanding |
33M | 9.6M |
| Jan 30, 2024 |
8-K filing: ArriVent BioPharma, Inc. filed its amended and restated certificate of incorporation and bylaws in connection with the closing of its initial public offering (IPO). The company completed its IPO of 9,722,222 shares of its common stock at a price of $18.00 per share, resulting in gross proceeds of approximately $175.0 million. ($175.0M proceeds) |
N/A | 9.6M |
| Jan 23, 2024 |
S-1/A filing: ArriVent BioPharma, Inc. is offering 8,333,333 shares of common stock in an initial public offering, with an estimated initial public offering price between $17.00 and $19.00 per share. |
N/A | 9.6M |
| Jan 22, 2024 |
S-1/A filing: This is an initial public offering of shares of common stock of ArriVent BioPharma, Inc. We are offering 8,333,333 shares of our common stock. |
N/A | 9.6M |